Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis

Table 2 Mean visual acuity in the triple combination therapy with zeaxanthin, triple combination therapy without zeaxanthin and control cohorts

Year	Triple combination therapy with zeaxanthin cohort	Triple combination therapy cohort	External control cohort (Shah and DelPriore)
1	20/200	20/250	20/200
2	20/160 + 2	20/200 + 1	20/250 − 2
3	20/160 + 2	20/200 + 1	20/320 − 2
4	20/160 + 2	20/200 + 1	20/400 − 1
5	20/160 + 2	20/200 + 1	20/500 + 1
6	20/160 + 2	20/200 + 1	20/500 − 1
7	20/160 + 2	20/200 + 1	20/500 − 2
8	20/160 + 2	20/200 + 1	20/500 − 2
9	20/160 + 2	20/200 + 1	20/640 + 1

ISSN: 2056-9920